not used title
not used title
For over a decade, Rare Disease Day has been celebrated on February 28 to raise awareness and generate change for the more than 30 million patients in the U.S. living with a rare disease. This year’s Rare Disease Day is particularly special because this year also marks the 40th anniversary of the Orphan Drug Act (ODA), allowing us to celebrate all the progress that’s come to patients because of it.
Here are some key things you should know about the ODA:
The ODA has supported the development of hundreds of new treatment options for patients living with rare diseases who previously had no options.
There are unique challenges of researching and developing medicines for diseases with a U.S. population of less than 200,000 people. Recognizing that, Congress passed the ODA in 1983 through bipartisan support. Because previous incentives had been insufficient, the ODA provides important targeted incentives to help protect investments in, and encourage companies to embark on, the necessary but risky research needed for rare disease drug development. Since the passage of the ODA, over 600 orphan drugs have been approved, including 20 new FDA approvals for rare diseases in 2022 alone. In the decade before the ODA was passed, only ten drugs were brought to market to treat rare diseases.
The unique challenges in developing new treatments for patients with rare diseases may deter investment in this area without the incentives of the ODA. Potential challenges include:
- The complexity of rare diseases and uncertainty about underlying causes
- Affected populations are small and may be spread out across the country, or world
- Physicians may be unfamiliar with the disease
- There may be many subtypes to the same disease, each with their own complexities
These considerations, along with the challenges of recruiting and retaining patients for trials, may impact the length and overall success rates of clinical trials for rare disease treatments. As of 2019, overall development for rare diseases takes nearly four years longer than non-rare disease conditions and the success rate of orphan drugs in clinical trials is estimated to be only six percent.
Despite significant progress in the fight to treat rare diseases, unmet patient needs remain.
Although each rare disease impacts less than 200,000 Americans, their impact on public health is far-reaching. In total, rare diseases affect more than 30 million Americans, but less than 10% of all rare diseases have a U.S. Food and Drug Administration (FDA) approved treatment. The need for new treatments and cures is reflected in the unique hardships and challenges that patients and their families face. Obtaining a diagnosis can be a long arduous process due to lack of physician awareness and access to screening. And once a diagnosis is obtained, often later in disease progression, the prognosis may be life threatening. The burden of rare disease is a driving factor in the commitment of the industry to help these patients and their families.
To help address these needs and improve the quality of life for patients and their families, biopharmaceutical researchers are committed to fighting rare diseases. In fact, today, there are more than 700 medicines in development to treat many of these devastating illnesses.
To meet the unmet needs of rare disease patients, policymakers must prioritize policies fostering innovation and not undermine the success of the ODA.
While the advancements of rare disease treatments are truly remarkable, last year, Congress took a step backwards by including drug price-setting provisions as part of the Inflation Reduction Act (IRA). These provisions undermine the previous bipartisan support for incentivizing rare disease drug development.
In particular, the law inadvertently discourages post-approval R&D, which is common in orphan drug development. For example, post approval R&D on medicines initially approved for use in adults with rheumatoid arthritis (RA) subsequently led to the approval of those medicines in juvenile idiopathic arthritis (JIA), providing children with this disease the ability to slow disease progression and prevent significant disability later in life. JIA is a group of six rare, often severe autoimmune or autoinflammatory diseases which cause the patient’s immune system to mistakenly attack the body’s own tissue. Post-approval research is critical in driving treatment advances for patients with orphan conditions such as JIA.
- In 2012, a medicine was approved to treat adults with RA. Additional research led to the discovery that adult RA was closely related to JIA, and the medicine was subsequently approved for patients two years and older who have a particular form of JIA impacting the joints (polyarticular JIA).
- In 2013, a different medicine was approved for adults with RA. In 2020 the medicine received two additional approvals for use in children and adolescents with 2 other forms of JIA that previously had no disease-modifying treatment options—including polyarticular JIA and another form (psoriatic).
R&D to develop treatments to address unmet needs in rare diseases is highly risky and takes significant time and investment. While the IRA does provide a specific exemption from price setting for medicines with a single orphan designation, the exemption is far too narrow and undermines the ODA incentives for developing new treatments for rare diseases. This forces companies to make hard choices when it comes to R&D investment. In a recent survey of PhRMA member companies on the impacts of the IRA, a majority reported that the price setting timelines in the law would cause them to reconsider investing in medicines for small patient populations and areas of high scientific uncertainty such as rare diseases.
Despite this new decision paradigm for rare disease R&D by the price setting provisions in the IRA, the biopharmaceutical industry is committed to fighting rare diseases just as they have for the last 40 years. On behalf of the scientists and researchers who have dedicated their life to rare disease patients and their families, I'm glad we get to celebrate and reflect on the progress we’ve made.
Abigail Lore
Abigail Lore, MPA, is Director of Policy and Research at PhRMA. At PhRMA she is responsible for developing educational materials and research studies on a range of issues impacting innovative biopharmaceutical companies including FDA policy issues, the R&D process, and emerging technologies such as digital health tools and cell and gene therapies. Before joining PhRMA in 2019, she worked at a patient advocacy organization as a project manager. Abigail came to Washington, DC via New Hampshire to attend American University, and fell in love with the city including the running and biking trails, endless restaurants to try and the DC sports teams. Abigail has seen the first hand benefits of biopharmaceutical research and is passionate about advocating for a strong STEM workforce as well as the patients they work to help.
Abigail Lore
New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums
September 18, 2026
Bayh-Dole: The fuel for America’s innovation engine
September 2, 2026
What AARP isn’t telling seniors about MFN
August 24, 2026
Policymakers should improve patient access and reject price controls
August 18, 2026
CMS proposal could discourage patient-centered innovation
August 18, 2026
ICYMI: Biopharmaceutical companies in America hit new investment milestone
August 14, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Voters continue to voice their concerns on government price controls
July 24, 2026
Medicare Part D at 20: Building on a strong foundation
July 23, 2026
Guest Blog: Price controls won’t lower costs when insurers control access
June 25, 2026
World Sickle Cell Day: Recognizing the promise of gene therapy
June 19, 2026
MFN could disrupt the affordable medicines patients depend on
June 18, 2026
New “America Cures” ad: U.S. patients get new medicines first
June 15, 2026
Patients speak out: MFN won't address my affordability concerns
June 4, 2026
MFN price controls threaten American jobs and the U.S. economy
May 28, 2026
America's cancer research progress is real and worth protecting
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
State price-setting boards create more questions than answers
May 20, 2026
New analysis highlights access to new medicines in the United States and abroad
May 13, 2026
MFN won’t lower costs when insurers call the shots
May 8, 2026
Guest Blog: How MFN price controls could decide my health care
April 30, 2026
MFN price controls would drain pensions and put retirements at risk
April 23, 2026
States should avoid repeating the IRA’s price‑setting mistakes
April 21, 2026
CMS undermines medical progress with MFN price controls
April 16, 2026
Trump Administration’s efforts to have other countries pay their fair share are underway
April 15, 2026
CMS’ MFN proposals won’t help seniors despite lofty promises
April 9, 2026
Voters voice concerns on government price controls
April 7, 2026
Virginia should be cautious about importing federal price-setting mechanisms
April 1, 2026
Policymakers shouldn’t double down on the IRA’s flaws with MFN
March 30, 2026
How AI is transforming the drug innovation lifecycle
March 19, 2026
MFN drug pricing risks reviving a harmful metric the U.S. rejected
March 16, 2026
Leadership in biopharmaceutical R&D provides U.S. patients the greatest access to innovative medicines
March 11, 2026
Harmful U.S. policies will help drive China’s global leadership in biopharmaceutical innovation
March 4, 2026
Celebrating rare disease innovation: Progress and the path forward
February 27, 2026
MFN undermines U.S. biopharmaceutical innovation
February 25, 2026
CMS puts patients and innovation at risk with MFN
February 24, 2026
Advancing patient care: A look at new medicines approved in 2025
January 30, 2026
New list of selected drugs highlights growing consequences of government price setting
January 28, 2026
Price setting policies put cancer gains in jeopardy
January 16, 2026
Myth vs. Fact: How government price setting impacts innovation
November 24, 2025
The IRA’s price setting doesn’t guarantee lower costs or better access
November 17, 2025
PhRMA calls on USTR to ensure foreign nations pay their fair share
November 4, 2025
What seniors can expect this open enrollment
October 14, 2025
Part D premiums are going up, while choices are going down
October 8, 2025
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
September 15, 2025
Celebrating 60 Years of Medicare
July 30, 2025
Medicare patients face higher drug costs, despite IRA promises
July 22, 2025
CMS continues to make a bad law worse
June 27, 2025
ICYMI: Forget Foreign Price Controls: There’s a better solution to lowering drug prices
June 26, 2025
What to know about vaccine ingredients: Aluminum and thimerosal
June 24, 2025
Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share
June 17, 2025
PhRMA Foundation celebrates 60 years of investing in future scientific leaders
June 11, 2025
New report: Post-approval innovation delivers substantial patient benefits
June 2, 2025
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
May 21, 2025
Foreign first pricing schemes don’t address why Americans pay more
May 15, 2025
New analysis: Fewer treatments and cures under the IRA’s pill penalty
May 1, 2025
How the IRA is impacting the generic drug market
April 8, 2025
Three reasons Congress should fix the IRA’s pill penalty
March 24, 2025
ICYMI: PhRMA submits comments to White House on artificial intelligence
March 17, 2025
4 things to know on Rare Disease Day
February 28, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report
February 21, 2025
New policy agenda charts solutions for a healthier America
February 20, 2025
A successful PhRMA Forum highlights our commitment to a healthier America
February 20, 2025
Guest Perspective: Prioritize Innovative Care
February 11, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
Virginia, Don't Let Politicians Take Away Your Medicine
January 23, 2025
Patients are losing as government price setting continues
January 17, 2025
PhRMA CEOs Tee Up Next Week's Health Care Conference
January 11, 2025
A new administration poses new opportunities for patient access
December 17, 2024
Congratulations to our 2024 Working for Cures Employee Champions
December 11, 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
CMS needs to do better
November 4, 2024
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
October 18, 2024
7 reasons why states shouldn’t copy the IRA’s price setting mistake
October 15, 2024
Did the administration consider the importance of blood cancer medicines to patients in price setting process?
October 8, 2024
New Report: Tackling chronic conditions with preventive treatment
September 30, 2024
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
September 25, 2024
Addressing the mounting threat of antimicrobial resistance
September 23, 2024
40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?
September 19, 2024
Three ways state drug price setting boards fail patients
September 18, 2024
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
September 17, 2024
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
September 16, 2024
New research: American biopharmaceutical investment in R&D drives transformational innovation
September 16, 2024
Did the administration consider the importance of autoimmune disease medicines to patients in price setting process?
September 11, 2024
Did the administration consider the value of innovative diabetes medicines in price setting process?
August 28, 2024
How to protect your children’s health this school year
August 22, 2024
New survey: Insurers confirm IRA will reduce patient treatment options
August 20, 2024
The unintended consequences of government price setting in Medicare Part D
August 16, 2024
Don’t put the government between patients and their medicines
August 7, 2024
Biosimilars continue to drive market competition and increase savings for seniors
August 6, 2024
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
August 1, 2024
What is the low-income subsidy program and how is it changing?
July 31, 2024
Three things to know about the United Nations’ new HIV/AIDS report
July 31, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
New Report: Vaccines continue to drive improved health outcomes
July 16, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm
July 3, 2024
More than 60 researchers advocate on Capitol Hill
July 1, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
Alzheimer's & Brain Awareness Month: A conversation with Biogen
June 27, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eisai
June 24, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
June 20, 2024
ICYMI: Health care policy should be driven by patients, not politics
June 10, 2024
ICYMI: Misaligned policies undermine patient access
June 6, 2024
Women’s Health Month: A conversation with Astellas
May 31, 2024
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
May 30, 2024
How the IRA is more coercive than any European government price setting scheme
May 29, 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
May 28, 2024
How government price setting fails to address systemic health care inequities
May 24, 2024
Women’s Health Month: A conversation with Sage
May 23, 2024
The use of real-world data in drug development
May 13, 2024
Government price-setting boards: Why Minnesota needs to take a better approach
May 9, 2024
New analysis: Accelerated approval pathway is changing lives in underserved communities
April 30, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
Government price setting won’t help patients in Illinois
April 22, 2024
New analysis: Flawed assessments of a medicine’s value jeopardize patient access
April 11, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
World Vaccine Congress: Building on vaccine success
April 1, 2024
The impact of innovative medicines: A caregiver's perspective
March 26, 2024
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
March 25, 2024
Colorado is proof: Too many unanswered questions remain about state government price setting's impact on patients and providers
March 14, 2024
What new cures would mean to families
March 7, 2024
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
February 29, 2024
American Heart Month: A nurse’s perspective
February 27, 2024
The truth about Nebraska's price setting push
February 13, 2024
Proposed march-in framework would chill American innovation
February 7, 2024
Three things to know about antibody drug conjugates
February 2, 2024
As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind
February 1, 2024
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
January 30, 2024
What they are saying: Experts agree that proposed march-in framework would jeopardize innovation
January 25, 2024
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
January 23, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
The White House continues to attack American innovation
December 15, 2023
Biosimilars drive savings, but the IRA undermines their development
December 14, 2023
Taking stock of obesity and its costly effects
December 8, 2023
Congratulations to our 2023 Working for Cures Employee Champions
December 6, 2023
Watch: Putting patients front and center for World AIDS Day
November 30, 2023
Misuse of march-in could stifle innovation
November 27, 2023
New analysis of patient access restrictions in the United Kingdom
November 21, 2023
WHO Pandemic Agreement offers opportunities and risks for American innovators
November 20, 2023
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
Don't close the door on rare disease research
November 13, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
Word of the Month: The Bayh-Dole Act
November 8, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
Three things economists are saying about the Inflation Reduction Act
October 11, 2023
Celebrating Hispanic Heritage Month at PhRMA
October 11, 2023
4 truths about state government price setting
October 10, 2023
Word of the Month: AMR
September 27, 2023
IRA threatens seniors’ access to robust treatment options
September 26, 2023
New PhRMA site demonstrates how a technology-driven health care system brings benefits to patients
September 11, 2023
Correcting the record: IRA’s government price setting provisions are unconstitutional
September 8, 2023
IRA changes to Part D risk access to medicines
August 24, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023
Three concerns about Colorado's approach to government price setting
August 23, 2023
With the first list of medicines out, let’s not forget why government price setting is bad policy
August 22, 2023
Michigan proposal jeopardizes access to medicines
August 21, 2023
One year later IRAs unintended consequences are becoming reality
August 16, 2023
AARP’s latest misleading report
August 11, 2023
Decentralized clinical trials and the future of drug development
August 9, 2023
WTAS on reasonable pricing and public-private partnerships
August 8, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
More than 60 researchers ask Congress to support innovation
June 26, 2023
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
June 22, 2023
Biopharmaceutical science powered by PRIDE
June 16, 2023
ASCO 2023: Protecting our progress in the fight against cancer
June 15, 2023
Reject efforts to undermine America’s R&D ecosystem
June 15, 2023
Highlights from ASCO 2023
June 8, 2023
Four things for CMS to keep in mind as they implement changes to Part D
June 7, 2023
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
May 30, 2023
Setting the record straight on accelerated approval
May 22, 2023
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
May 11, 2023
Support for continued progress is critical for pediatric drug development
May 8, 2023
New resource underscores the importance of small molecule medicines
May 4, 2023
Policies need to address the growing threat of antimicrobial resistance
April 28, 2023
World IP Day 2023: Celebrating women leaders in innovation
April 26, 2023
CMS guidance on IRA price setting process doubles down on bad policy
April 14, 2023
A guide to MedPAC’s Part B vote today
April 13, 2023
New global analysis shows patient access challenges around the world
April 12, 2023
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
April 7, 2023
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
March 28, 2023
Celebrating the success of the COVID-19 vaccines, and looking to the future
March 27, 2023
IRA Impacts: Cancer treatment research and development
March 23, 2023
PhRMA submits comments to OSTP on enhancing clinical trial diversity
March 21, 2023
What we’ve learned from three years of fighting COVID-19
March 20, 2023
PhRMA submits comments to USPTO highlighting important role of patent system in medicine development
February 23, 2023
State policymakers can protect American innovation and help Americans live longer, healthier lives
February 9, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
WTAS: Inflation Reduction Act already impacting R&D decisions
January 17, 2023
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
December 9, 2022
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
December 1, 2022
Expanding TRIPS waiver would jeopardize biopharmaceutical research and development
November 17, 2022